GH Research Reports Second Quarter 2024 Financial Results, Provides Corporate Updates

• Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1 2025
• Phase 1 clinical trial evaluating a patented aerosol delivery device in healthy adult subjects approved in the UK and seeking new patients
• Cash, cash equivalents, other financial assets and marketable securities of $204.5 million

DUBLIN, Sept. 3, 2024 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company focused on transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2024 and provided an update on its operations.

Business updates